Smith & Nephew plc (LSE: SN., NYSE: SNN), the global medical technology company with annual sales of $6.2 billion, has commenced the second and final tranche of its share buyback programme, engaging Merrill Lynch International to purchase up to $250 million worth of ordinary shares. The programme, originally announced on 6 May 2026, begins on 11 November 2026 and will run no later than 23 April 2027. The move is designed to reduce Smith & Nephew's issued share capital by returning surplus capital to shareholders, a development likely to be monitored closely by investors in the FTSE 100 constituent.

Key Points

  • Smith & Nephew plc (LSE: SN., NYSE: SNN) is a global medical technology business founded in Hull in 1856, now operating in around 100 countries
  • The company has launched the second and final tranche of its share buyback programme, with Merrill Lynch International acting as riskless principal
  • Up to $250 million in ordinary shares may be purchased, capped at a maximum of 68,250,000 shares, within authority granted at the 2026 Annual General Meeting
  • Investors should watch for further announcements from Smith & Nephew confirming individual share repurchases as the programme progresses to April 2027

Merrill Lynch International to Act as Riskless Principal in $250 Million Buyback Tranche

Under a non-discretionary agreement, Merrill Lynch International will purchase Smith & Nephew ordinary shares of USD $0.20 each on the open market, with the company subsequently repurchasing those shares from Merrill Lynch International. The announcement confirms that shares acquired will be held as treasury shares and may then either be cancelled or retained to satisfy awards under employee share plans. Purchases will be carried out on Recognised Investment Exchanges including the London Stock Exchange, Cboe Europe Limited, Turquoise, and Aquis Stock Exchange, subject to pre-set parameters.

Maximum of 68,250,000 Ordinary Shares Permitted Under 2026 AGM Authority

The maximum number of ordinary shares that may be repurchased under this second tranche is 68,250,000, the announcement states, which falls within the remaining authority granted by shareholders at Smith & Nephew's 2026 Annual General Meeting. The programme will be conducted in accordance with Market Abuse Regulation 596/2014/EU as retained in domestic UK law, and within the parameters of Chapter 9 of the Financial Conduct Authority's UK Listing Rules. The company confirmed that no repurchases will be made in respect of its American Depositary Receipts listed on the NYSE.

Smith & Nephew's $6.2 Billion Medical Technology Business Across Orthopaedics, Sports Medicine and Wound Management

Smith & Nephew is a portfolio medical technology business employing approximately 17,000 people globally, focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates across three business units — Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management — generating annual sales of $6.2 billion in 2025. Founded in Hull in 1856, Smith & Nephew now operates in around 100 countries. The company noted there is no guarantee the programme will be implemented in full or that any shares will ultimately be repurchased, representing a material caveat for investors tracking capital return progress.